Tougher market conditions impacting Angle clients
5th Jan 2023 16:09
(Sharecast News) - Liquid biopsy specialist Angle said in an update on Thursday that actions taken to control its cost base, and the closure of its Canadian operations, left it on track to deliver expected cost savings of £2.6m in 2023 and £4m per annum after that.
Read moreDirector dealings: Angle CEO, finance chief join capital raise
19th Jul 2022 16:35
(Sharecast News) - Liquid biopsy specialist Angle had two entries on the list of director buys on Tuesday, after its chief executive and chief financial officers invested in shares.
Read moreAngle wins additional contract with large-scale pharma company
22nd Jun 2022 10:27
(Sharecast News) - Liquid biopsy company Angle has secured an additional contract with its first large-scale pharmaceutical services customer.
Read moreAngle's Parsortix to be used in 'significant' prostate cancer study
20th May 2022 13:07
(Sharecast News) - Liquid biopsy company Angle announced on Friday that Prostate Cancer UK has approved funding for a "significant" clinical study at the Barts Cancer Institute of the Queen Mary University of London.
Read moreAngle agrees pharma services contract with new customer
28th Jul 2021 15:23
(Sharecast News) - Liquid biopsy company Angle has agreed a pharma services contract with another new customer, it announced on Wednesday, for its recently-established pharma services business.
Read moreAngle completes patient enrolment for ovarian cancer study
26th Apr 2021 11:38
(Sharecast News) - Liquid biopsy company Angle announced on Monday that its 200-patient ovarian cancer clinical verification study had completed patient enrolment.
Read moreAngle secures first large-scale pharma services contract
16th Apr 2021 12:31
(Sharecast News) - Liquid biopsy company Angle has secured its first large-scale pharma services contract, it announced on Friday.
Read moreAngle completes clinical labs in Guildford and Pennsylvania
30th Mar 2021 15:39
(Sharecast News) - Liquid biopsy company Angle has completed the fitout and staffing of its clinical services laboratories in Guildford and Pennsylvania, it announced on Tuesday.
Read moreFDA accepts Angle's review submission for Parsortix PC1
20th Oct 2020 08:58
(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the US Food and Drug Administration (FDA) has completed its administrative review, and accepted the company's submission for substantive review.
Read moreAngle's 'Parsortix' advantageous in breast cancer in new research
20th Jul 2020 10:16
(Sharecast News) - Angle announced on Monday that the University of Southern California (USC) has published peer-reviewed results of new work undertaken in metastatic breast cancer (MBC), highlighting advantages of a 'Parsortix' liquid biopsy, compared to standard-of-care tissue biopsy.
Read moreAngle upbeat on recent research using 'Parsortix'
12th May 2020 08:58
(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the liquid biopsy analysis unit at the Health Research Institute of Santiago in Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer, on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs).
Read moreAngle works with skeleton R&D crew during lockdown
28th Apr 2020 10:03
(Sharecast News) - Biopharmaceuticals group Angle said on Tuesday that progress had been impeded by the Covid-19 outbreak as the firm worked with a research and development skeleton crew in Guildford.
Read moreAngle UK, US, Canada operations 'severely disrupted' by Covid-19
31st Mar 2020 09:40
(Sharecast News) - Liquid biopsy company Angle said on Tuesday that operations in the UK, US and Canada had all been "severely disrupted" by the Covid-19 pandemic.
Read moreAngle upbeat on recent Parsortix research out of Italy
27th Feb 2020 12:42
(Sharecast News) - Liquid biopsy company Angle announced on Thursday that Istituto Nazionale Tumori di Milano in Milan, Italy, has published results of work assessing the performance of its 'Parsortix' system in renal cell carcinoma (RCC), demonstrating key advantages of Parsortix.
Read moreAngle upbeat on German research into 'Parsortix'
17th Feb 2020 15:25
(Sharecast News) - Liquid biopsy company Angle announced on Monday that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of 'Parsortix' in multiple metastatic cancer types, with the main emphasis on metastatic breast cancer.
Read more